{"questions": [

    {
        "body": "What is the most prominent sequence consensus for the polyadenylation site?", 
        "concepts": [
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D026723", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011061", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D039221", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D039104", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016384", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011063", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012313", 
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0043631", 
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=1900363"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/1915889", 
            "http://www.ncbi.nlm.nih.gov/pubmed/1993703", 
            "http://www.ncbi.nlm.nih.gov/pubmed/6194440", 
            "http://www.ncbi.nlm.nih.gov/pubmed/7901430", 
            "http://www.ncbi.nlm.nih.gov/pubmed/1712333", 
            "http://www.ncbi.nlm.nih.gov/pubmed/2513486"
        ], 
        "exact_answer": [
            [
                "AATAAA"
            ], 
            [
                "AAUAAA"
            ]
        ], 
        "id": "5133b9455274a5fb0700000c", 
        "ideal_answer": "Functional polyadenylation [poly(A)] sites consist of two sequence elements, the AAUAAA and G/U box signals, that closely flank the site of mRNA 3'-end formation. The canonical polyadenylation signal sequence AATAAA", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/1915889", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 364, 
                "offsetInEndSection": 417, 
                "text": "the cannonical polyadenylation signal sequence AATAAA"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/1993703", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1178, 
                "offsetInEndSection": 1235, 
                "text": "Two AATAAA motifs are coded in the last exon of this gene"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/6194440", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 236, 
                "offsetInEndSection": 407, 
                "text": "The results demonstrate that the intact AAUAAA is not required for RNA polyadenylation but is required for the cleavage step preceding polyadenylation to occur efficiently"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/7901430", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 464, 
                "offsetInEndSection": 532, 
                "text": "the early poly(A) consensus signal was mutated from AAUAAA to UGUAAA"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/1712333", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 161, 
                "text": "Functional polyadenylation [poly(A)] sites consist of two sequence elements, the AAUAAA and G/U box signals, that closely flank the site of mRNA 3'-end formation"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/1712333", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 849, 
                "offsetInEndSection": 944, 
                "text": "the appropriate spacing of the AAUAAA and G/U box signals is critical for poly(A) site function"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/2513486", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 189, 
                "offsetInEndSection": 320, 
                "text": " Two AATAAA hexanucleotide sequences are present in the 2092 nucleotide interval. The first one functions as the major polyA signal"
            }
        ], 
        "type": "list"
    }, 

    {
        "body": "Which extra thyroid tissues have thyrotropin (TSH) receptors?", 
        "concepts": [
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011989", 
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0004996", 
            "http://www.biosemantics.org/jochem#4250044"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/22517745", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22496347", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22399514", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22289392", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21956421"
        ], 
        "exact_answer": [
            [
                "adipose tissue"
            ], 
            [
                "fibrotic tissue"
            ]
        ], 
        "id": "513f45abbee46bd34c000013", 
        "ideal_answer": "TSH receptors are expressed also in extrathyroid tissues. TSH receptors seem to be functional. Extrathyroid tissues include fibrobasts of the orbit and adipose tissue\nThe principal tissues with TSH receptors are:\nadippose tissue\n orbital fibrotic tissue", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22517745", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1217, 
                "offsetInEndSection": 1336, 
                "text": "GD orbital fibroblasts, which comprise a mixture of CD34(+) and CD34(-) cells, express much lower levels of Tg and TSHR"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22517745", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 552, 
                "offsetInEndSection": 731, 
                "text": "Previously, we found that CD34(+) progenitor cells, known as fibrocytes, express functional TSHR, infiltrate the orbit, and comprise a large subset of orbital fibroblasts in TAO. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22496347", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 882, 
                "offsetInEndSection": 923, 
                "text": "TSH induced lipolysis in adipose tissues."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22496347", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1376, 
                "offsetInEndSection": 1434, 
                "text": "TSH worked as a lipolytic factor in white adipose tissues,"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21956421", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 303, 
                "offsetInEndSection": 439, 
                "text": "These fibrocytes infiltrate orbital connective tissues in thyroid-associated ophthalmopathy and express functional TSH receptor (TSHR). "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21956421", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1047, 
                "offsetInEndSection": 1104, 
                "text": "TSHR levels are higher than those in orbital fibroblasts."
            }
        ], 
        "type": "list"
    }, 
            {
        "body": "Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome?", 
        "concepts": [
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018761", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009369"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/23435440", 
            "http://www.ncbi.nlm.nih.gov/pubmed/23279763", 
            "http://www.ncbi.nlm.nih.gov/pubmed/23024266", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21613051", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21302639", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20175448", 
            "http://www.ncbi.nlm.nih.gov/pubmed/18172277", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17455252", 
            "http://www.ncbi.nlm.nih.gov/pubmed/11914929", 
            "http://www.ncbi.nlm.nih.gov/pubmed/10664520", 
            "http://www.ncbi.nlm.nih.gov/pubmed/10614532", 
            "http://www.ncbi.nlm.nih.gov/pubmed/10502325", 
            "http://www.ncbi.nlm.nih.gov/pubmed/10496602", 
            "http://www.ncbi.nlm.nih.gov/pubmed/9820618", 
            "http://www.ncbi.nlm.nih.gov/pubmed/9735087", 
            "http://www.ncbi.nlm.nih.gov/pubmed/9236523", 
            "http://www.ncbi.nlm.nih.gov/pubmed/7962349"
        ], 
        "exact_answer": [
            [
                "parathyroid gland"
            ], 
            [
                "pancreas"
            ], 
            [
                "pituitary gland"
            ]
        ], 
        "id": "51477de5d24251bc05000020", 
        "ideal_answer": "Multiple endocrine neoplasia type 1 syndrome is an inherited cancer syndrome defined by occurrence of multiple neuro-endocrine tumors and is classically associated with the combined occurrence of two or more tumors involving parathyroid gland, pancreas and pituitary gland. Other tumors, including but not limited to adrenal cortical tumor, carcinoid tumors lipoma, leiomyoma, duodenal gastrinoma, hepatic focal nodular hyperplasia, and renal angiomyolipoma, angiofibroma, colagenoma, thyroid tumor and meningioma, may also be present.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23435440", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 275, 
                "text": "Multiple endocrine neoplasia type 1 (MEN1; formerly known as Wermer syndrome) is a rare disorder characterized by the combined occurrence of two or more tumors involving parathyroid, pancreatic islets and anterior pituitary glands; some other tumors have also been described."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23435440", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 950, 
                "offsetInEndSection": 1154, 
                "text": " Hyperparathyroidism is the most common feature of MEN1 (95% of patients), pancreatic islet tumors or pancreatic NET (neuroendocrine tumor) occur in 40-70% and pituitary tumors in 30-40% of MEN 1 patients"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23435440", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1155, 
                "offsetInEndSection": 1302, 
                "text": " In addition, other tumors, such as adrenal cortical tumors, carcinoid tumors, lipomas, angiofibromas, colagenomas and meningiomas may be present. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23435440", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1705, 
                "offsetInEndSection": 1803, 
                "text": "the most important causes malignant pancreatic neuroendocrine tumors (NET) and thymic carcinoids. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23279763", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 292, 
                "text": "Multiple endocrine neoplasia type 1 (MEN1) is inherited in an autosomal dominant fashion and predisposes to the development of hyperplastic or neoplastic changes in the parathyroid and pituitary glands and the endocrine pancreas, along with numerous other characteristic tumors and features. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23024266", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 224, 
                "text": "Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterized by the combined occurrence of parathyroid and adrenocortical tumors, and neuroendocrine tumors (NETs) of the pancreas and pituitary. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23024266", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 224, 
                "offsetInEndSection": 362, 
                "text": "The pancreatic NETs are predominantly gastrinomas and insulinomas, and the pituitary NETs are mostly prolactinomas and somatotrophinomas. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21613051", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 461, 
                "offsetInEndSection": 617, 
                "text": "We address the potential role of miRNAs in the endocrine pancreas, the pituitary gland, and the parathyroid glands-areas where MEN 1 shows high penetrance. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21613051", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 749, 
                "offsetInEndSection": 921, 
                "text": "Moreover, studies have provided evidence that dysregulation of miRNAs was responsible for endocrine carcinogenesis, including pancreatic, pituitary, and parathyroid tumors."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21302639", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 111, 
                "text": "MEN1 and MEN2 are rare inherited cancer syndromes which express a variety of endocrine and nonendocrine tumors."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20175448", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 141, 
                "text": "Multiple endocrine neoplasia Type 1 (MEN1) is a rare hereditary tumor syndrome predisposing to tumor development in several endocrine organs."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20175448", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 141, 
                "offsetInEndSection": 240, 
                "text": " Its major manifestations include hyperparathyroidism, tumors of endocrine pancreas and pituitary. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20175448", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 241, 
                "offsetInEndSection": 459, 
                "text": "eside these three, several other endocrine (adrenocortical, foregut carcinoid) and nonendocrine (lipoma, angiofibroma, collagenoma, ependymoma, meningioma) tumors have been described to be associated with this syndrome"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20175448", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 461, 
                "offsetInEndSection": 764, 
                "text": "Both familial and sporadic forms of the disease are known. The diagnosis of MEN1 can be established if two of the three major manifestations are found in the same patient, whereas the diagnosis of familial MEN1 requires one MEN1 patient and a first degree relative with at least one MEN1 manifestation. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20175448", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 875, 
                "offsetInEndSection": 997, 
                "text": "Both benign (parathyroid, anterior pituitary) and malignant (gastrinoma, glucagonoma) lesions may develop in MEN1 patients"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11914929", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 203, 
                "text": "Multiple endocrine neoplasia type 1 (MEN1) is a classic hereditary tumor syndrome characterized by a genetic predisposition to develop a variety of neuroendocrine neoplasias and hormone excess syndromes."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10664520", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 136, 
                "text": "Multiple endocrine neoplasia type 1 (MEN 1) is a familial syndrome characterized by parathyroid, enteropancreatic and pituitary tumors. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/9820618", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 154, 
                "text": "Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant inherited tumor syndrome characterized by the development of multiple endocrine tumors"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/9236523", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 698, 
                "offsetInEndSection": 1175, 
                "text": "Multiple facial angiofibromas were observed in 28 (88%) of the patients with MEN1, with 16 patients (50%) having 5 or more. Angiofibromas were clinically and histologically identical to those in individuals with tuberous sclerosis. Collagenomas were observed in 23 patients (72%). Also observed were cafe au lait macules in 12 patients (38%), lipomas in 11 patients (34%), confetti-like hypopigmented macules in 2 patients (6%), and multiple gingival papules in 2 patients (6%)"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/9236523", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1190, 
                "offsetInEndSection": 1484, 
                "text": "Multiple angiofibromas, collagenomas, lipomas, confetti-like hypopigmented macules and multiple gingival papules are cutaneous manifestations of MEN1 and should be looked for in both family members of patients with MEN1 and individuals with hyperparathyroidism of other MEN1-associated tumors. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/7962349", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 266, 
                "text": "Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant inherited disorder characterized by nodular proliferation of the parathyroid glands and tumors of the anterior pituitary gland, the endocrine pancreas, and the neuroendocrine cell system of the gut."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/7962349", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 400, 
                "offsetInEndSection": 613, 
                "text": "We report here a genetic study of a female MEN1 patient with the association of nodular hyperplasia of two parathyroid glands, an insulinoma, multiple duodenal gastrinomas, a prolactinoma, and a gastric carcinoid."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/18172277", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 11, 
                "offsetInEndSection": 213, 
                "text": "Multiple endocrine neoplasia type 1 (MEN1) is defined clinically by the combined occurrence of multiple tumors, typically of the parathyroid glands, pancreatic islet cells, and anterior pituitary gland."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17455252", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1125, 
                "offsetInEndSection": 1485, 
                "text": "In support of previous findings in islet tumors, we found down-regulation of the cell-cycle regulator, p18, in both the pancreatic islet and pituitary adenomas, suggesting that reduced p18 levels may be important for Men1-related tumorigenesis in multiple tissues. Surprisingly, we identified increased p16 transcript in pancreatic islet and pituitary tumors. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10614532", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 163, 
                "offsetInEndSection": 458, 
                "text": " The patient was studied and diagnosed with a multiple endocrine neoplasia type I (MEN I), familiar (mother with MEN I). A scintigraphic study with 99mTc-MIBI was performed in order to localize hyperfunctioning parathyroid glands because of biochemical diagnosis of primary hyperparathyroidism. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10614532", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 761, 
                "offsetInEndSection": 869, 
                "text": "The tumor was removed and histologically confirmed as a carcinoid within a thymus in a MEN type I syndrome. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10614532", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 869, 
                "offsetInEndSection": 1040, 
                "text": "MEN I patients can benefit from the examination with this agent which can potentially localize not only parathyroid endocrine pathology but also unknown associated tumors."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10502325", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 149, 
                "text": "Pancreatic endocrine tumors occur sporadically and as part of the multiple endocrine neoplasia type 1 (MEN 1) and von Hippel-Lindau (VHL) syndromes. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10502325", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 436, 
                "offsetInEndSection": 701, 
                "text": "We have analyzed 22 nonfamilial and 16 MEN 1-associated pancreatic endocrine tumors for loss of heterozygosity (LOH) at 3p, 11q13, and 18q. LOH at 3p was revealed in 45% and 36% of tumors from 31 patients with nonfamilial and MEN 1-associated disease, respectively."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10502325", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1470, 
                "offsetInEndSection": 1670, 
                "text": "The data indicate involvement of tumor suppressor genes on 3p and 18q, in addition to the MEN1 gene at 11q13, in the tumorigenesis of both nonfamilial and MEN 1-associated pancreatic endocrine tumors."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10496602", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 282, 
                "text": "Multiple endocrine neoplasia type 1 (MEN1) is characterized by the development of endocrine tumors of the parathyroid and pituitary glands, pancreas, and duodenum. Less frequently occurring tumors associated with MEN1 include non-endocrine tumors such as lipomas and angiofibromas. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10496602", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 282, 
                "offsetInEndSection": 468, 
                "text": "An increased incidence of thyroid neoplasms, leiomyomas, adrenal cortical hyperplasia, hepatic focal nodular hyperplasia, and renal angiomyolipoma has been noted in the MEN1 population. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10496602", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 768, 
                "offsetInEndSection": 1055, 
                "text": "A germline mutation of the MEN1 gene was detected, and deletions of the MEN1 gene were consistently detected in multiple neuroendocrine tumors involving the parathyroid glands and the pancreas and a hepatic neuroendocrine tumor metastasis, as predicted by Knudson's \"two hit\" hypothesis."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10496602", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1071, 
                "offsetInEndSection": 1232, 
                "text": "Two hits of the MEN1 gene were also detected in esophageal leiomyoma tissue, suggesting that tumorigenesis was directly related to the patient's underlying MEN1."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10496602", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1237, 
                "offsetInEndSection": 1612, 
                "text": " In contrast, follicular thyroid adenoma, papillary thyroid carcinoma, hepatic focal nodular hyperplasia, and adrenal cortical hyperplasia consistently showed retained heterozygosity of the MEN1 gene with flanking markers and an intragenic marker. Therefore, these tumors appear to develop along pathogenetic pathways that are different from classical MEN1-associated tumors."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/9820618", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 312, 
                "offsetInEndSection": 624, 
                "text": "Twelve unrelated (German MEN1 families and their associated tumors (5 parathyroid tumors, 1 vipoma, 1 gastrinoma, 1 insulinoma) were characterized for MEN1 gene mutations by single-strand conformational variant (SSCV) analysis and DNA sequence analysis as well as for loss of heterozygosity on chromosome 11q13. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/9735087", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 277, 
                "text": "Multiple endocrine neoplasia type 1 (MEN1) consists of benign, and sometimes malignant, tumors (often multiple in a tissue) of the parathyroids, enteropancreatic neuroendocrine system, anterior pituitary, and other tissues. Skin angiofibromas and skin collagenomas are common. "
            }
        ], 
        "type": "list"
    }, 
        {
        "body": "Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis?", 
        "concepts": [
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009157", 
            "http://www.disease-ontology.org/api/metadata/DOID:437", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002800", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000110", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004791"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/21328290", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21133188", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20663605", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21815707", 
            "http://www.ncbi.nlm.nih.gov/pubmed/15610702", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21845054"
        ], 
        "exact_answer": [
            [
                "neostigmine"
            ], 
            [
                "pyridostigmine"
            ]
        ], 
        "id": "5149199dd24251bc05000040", 
        "ideal_answer": "Pyridostigmine and neostygmine are acetylcholinesterase inhibitors that are used as first-line therapy for symptomatic treatment of myasthenia gravis. Pyridostigmine is the most widely used acetylcholinesterase inhibitor. Extended release pyridotsygmine and novel acetylcholinesterase inhibitors inhibitors with oral antisense oligonucleotides are being studied.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21133188", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1251, 
                "offsetInEndSection": 1321, 
                "text": "Pyridostigmine is the most widely used acetylcholinesterase inhibitor."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20663605", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 12, 
                "offsetInEndSection": 171, 
                "text": "For more than 50 years the acetylcholinesterase inhibitor pyridostigmine bromide has been the drug of choice in the symptomatic therapy for myasthenia gravis. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20663605", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 871, 
                "offsetInEndSection": 1229, 
                "text": "The switch to SR-Pyr ameliorated the total quantified myasthenia gravis (QMG) score from 0.9 \u00b1 0.5 to 0.6 \u00b1 0.4 (p<0.001) in all patients and in the younger subgroup. This was accompanied by a significant improvement in the quality of life parameters. The health status valued by EuroQoL questionnaire improved from 0.626 \u00b1 0.286 to 0.782 \u00b1 0.186 (p<0.001). "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20663605", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1412, 
                "offsetInEndSection": 1578, 
                "text": "Our results support the usefulness of SR-Pyr in an individualized therapeutic regimen to improve quality of life regardless of the patient's age in myasthenia gravis."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21815707", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 476, 
                "offsetInEndSection": 571, 
                "text": "This review focuses on treatment of MG, mainly on the use of the AChE inhibitor pyridostigmine."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21815707", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 572, 
                "offsetInEndSection": 768, 
                "text": "Despite a lack of data from well controlled clinical trials to support their use, AChE inhibitors, of which pyridostigmine is the most commonly used, are recommended as first-line therapy for MG. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21815707", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1071, 
                "offsetInEndSection": 1197, 
                "text": "Novel AChE inhibitors with oral antisense oligonucleotides have been developed and preliminary results appear to be promising."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21328290", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 2418, 
                "offsetInEndSection": 2808, 
                "text": "Except for one small and inconclusive trial of intranasal neostigmine, no randomised controlled trial has been conducted on the use of acetylcholinesterase inhibitors in myasthenia gravis. Response to acetylcholinesterase inhibitors in observational studies is so clear that a randomised controlled trial depriving participants in the placebo arm of treatment would be difficult to justify."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21815707", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 178, 
                "offsetInEndSection": 475, 
                "text": " Current guidelines and recommendations for MG treatment are based largely on clinical experience, retrospective analyses and expert consensus. Available therapies include oral acetylcholinesterase (AChE) inhibitors for symptomatic treatment, and short- and long-term disease-modifying treatments."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21815707", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 768, 
                "offsetInEndSection": 1071, 
                "text": "Pyridostigmine has been used as a treatment for MG for over 50 years and is generally considered safe. It is suitable as a long-term treatment in patients with generalized non-progressive milder disease, and as an adjunctive therapy in patients with severe disease who are also receiving immunotherapy. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15610702", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 343, 
                "offsetInEndSection": 452, 
                "text": "Acetylcholinesterase inhibitors provide temporary, symptomatic treatment for all forms of myasthenia gravis. "
            }, 
            {
                "beginSection": "sections.1", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21845054", 
                "endSection": "sections.1", 
                "offsetInBeginSection": 52, 
                "offsetInEndSection": 340, 
                "text": "In MG, the first-line option is symptomatic treatment with acetylcholinesterase inhibitors. Pyridostigmine bromide is the most commonly used drug. Other acetylcholinesterase inhibitors such as neostigmine are rarely used because of their poorer pharmacodynamic profiles and tolerability. "
            }, 
            {
                "beginSection": "sections.1", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21845054", 
                "endSection": "sections.1", 
                "offsetInBeginSection": 339, 
                "offsetInEndSection": 659, 
                "text": " In an observational study of 14 MG patients comparing pyridostigmine with neostigmine, it was concluded that over 1 year, pyridostigmine was more effective with less adverse events.5 Similar conclusions were reached in another observational study of 69 patients which compared the use of pyridostigmine with neostigmine"
            }
        ], 
        "type": "list"
    }, 
                {
        "body": "In which isochores are Alu elements enriched?", 
        "concepts": [
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D032085", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020087"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/22057813", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19543403", 
            "http://www.ncbi.nlm.nih.gov/pubmed/15871047", 
            "http://www.ncbi.nlm.nih.gov/pubmed/11591470", 
            "http://www.ncbi.nlm.nih.gov/pubmed/9931467", 
            "http://www.ncbi.nlm.nih.gov/pubmed/8828040", 
            "http://www.ncbi.nlm.nih.gov/pubmed/7723057", 
            "http://www.ncbi.nlm.nih.gov/pubmed/6572942"
        ], 
        "exact_answer": [
            [
                "H2"
            ], 
            [
                "H3"
            ]
        ], 
        "id": "515bd543298dcd4e51000001", 
        "ideal_answer": "Alu elements are enriched in high GC% isochores due to reduced Alu loss by recombination in these regions. The frequency of Alu sequences increases with increasing GC, but attains a maximum in H2 isochores.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22057813", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 146, 
                "offsetInEndSection": 241, 
                "text": " the vast majority of Alu sequences were shown to have the highest density in GC-rich isochores"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22057813", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 988, 
                "offsetInEndSection": 1103, 
                "text": "Alu sequences being unstable in the GC-poor isochores but stable in the compositionally matching GC-rich isochores,"
            }, 
            {
                "beginSection": "sections.2", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19543403", 
                "endSection": "sections.2", 
                "offsetInBeginSection": 257, 
                "offsetInEndSection": 406, 
                "text": "he increase in insertions and deletions in the H1-H3 isochore families, parallels the increase in the concentration of both Alu sequences and genes ("
            }, 
            {
                "beginSection": "sections.1", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19543403", 
                "endSection": "sections.1", 
                "offsetInBeginSection": 3306, 
                "offsetInEndSection": 3561, 
                "text": "The density of insertions/deletions increased with increasing GC of isochore families, essentially paralleling the densities of genes and Alu sequences, except for the lower values of the longest (>1000 bp, base pairs) insertions/deletions in H3 isochores"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15871047", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 152, 
                "text": "Alu retrotransposons do not show a homogeneous distribution over the human genome but have a higher density in GC-rich (H) than in AT-rich (L) isochores"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15871047", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1230, 
                "offsetInEndSection": 1463, 
                "text": "This result, together with the known higher selective disadvantage of recombination products in H isochores, points to Alu-Alu recombination as the main agent provoking the density shift of Alus toward the GC-rich parts of the genome"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11591470", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 175, 
                "offsetInEndSection": 235, 
                "text": "whereas GC-rich Alus are mostly present in GC-rich isochores"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11591470", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1221, 
                "offsetInEndSection": 1469, 
                "text": "the present results on Alu and LINE stability/exclusion predict significant losses of Alu DNA from the GC-poor isochores during evolution, a phenomenon apparently due to negative selection against sequences that differ from the isochore composition"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/9931467", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 780, 
                "offsetInEndSection": 929, 
                "text": "The frequency of Alu sequences also increases with increasing GC, but attains a maximum in H2 isochores, in agreement with previous experimental data"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/9931467", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1570, 
                "offsetInEndSection": 1643, 
                "text": "The CpG levels of both Alus and CpG islands increase with their GC levels"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/8828040", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 327, 
                "offsetInEndSection": 416, 
                "text": "characterized as a GC-rich isochore enriched for CpG islands, genes, and Alu-like repeats"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/7723057", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1299, 
                "offsetInEndSection": 1414, 
                "text": "Microsatellites and SINES (Alu, B1, B2) are found at roughly equal frequencies in introns from all isochore classes"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/6572942", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 500, 
                "offsetInEndSection": 776, 
                "text": "The results indicate that the short repeats of the B1 family of mouse and of the Alu I family of man are most frequent in the heavy components, whereas the long repeats of the BamHI family of mouse and of the Kpn I family of man are mainly present in the two light components."
            }
        ], 
        "type": "list"
    }, 
    {
        "body": "Which forms of cancer is the Tpl2 gene associated with?", 
        "concepts": [
            "http://www.disease-ontology.org/api/metadata/DOID:162", 
            "http://www.uniprot.org/uniprot/M3K8_RAT"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/23457529", 
            "http://www.ncbi.nlm.nih.gov/pubmed/23064365", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22451924", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21267413", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20935675", 
            "http://www.ncbi.nlm.nih.gov/pubmed/15575964"
        ], 
        "exact_answer": [
            [
                "Skin cancer"
            ], 
            [
                "ADI prostate cancer"
            ], 
            [
                "gastric adenocarcinoma"
            ], 
            [
                "colon adenocarcinoma"
            ], 
            [
                "colitis-associated cancer (CAC)"
            ], 
            [
                "breast cancer"
            ], 
            [
                "Hodgkin lymphoma"
            ], 
            [
                "nasopharyngeal carcinoma"
            ], 
            [
                "T-cell neoplasia"
            ]
        ], 
        "id": "515bf6d6298dcd4e51000004", 
        "ideal_answer": "Tpl2/Map3K8, also known as tumor progression locus 2 has been identified as an oncogene, its mutation or overexpression is reported in a variety of human cancers. Types of cancer associated with Tpl2 include skin and epithelial cancers, ADI prostate cancer, gastric and colon adenocarcinomas, colitis-associated cancer (CAC), breast cancer, Hodgkin lymphomas, nasopharyngeal carcinomas and several types of T-cell neoplasias.", 
        "snippets": [
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23457529", 
                "endSection": "title", 
                "offsetInBeginSection": 44, 
                "offsetInEndSection": 94, 
                "text": "increased skin tumorigenesis in tpl2 knockout mice"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23457529", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1464, 
                "offsetInEndSection": 1596, 
                "text": "These experiments illustrate COX-2 induction in the absence of Tpl2 may be responsible for the increased tumorigenesis found in mice"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23064365", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1344, 
                "offsetInEndSection": 1485, 
                "text": "These findings establish a mesenchyme-specific role for Tpl2 in the regulation of HGF production and suppression of epithelial tumorigenesis."
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23064365", 
                "endSection": "title", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 96, 
                "text": "Tpl2 regulates intestinal myofibroblast HGF release to suppress colitis-associated tumorigenesis"
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22451924", 
                "endSection": "title", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 64, 
                "text": "Tpl2 ablation promotes intestinal inflammation and tumorigenesis"
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21267413", 
                "endSection": "title", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 102, 
                "text": "TPL2/COT/MAP3K8 (TPL2) activation promotes androgen depletion-independent (ADI) prostate cancer growth"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21267413", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 3926, 
                "offsetInEndSection": 4136, 
                "text": "the suppression of TPL2 diminishes ADI prostate cancer growth and a high frequency of TPL2 overexpression in human ADI prostate cancer samples validates TPL2 as a target for the treatment of this deadly disease"
            }, 
            {
                "beginSection": "sections.4", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21267413", 
                "endSection": "sections.4", 
                "offsetInBeginSection": 6982, 
                "offsetInEndSection": 7091, 
                "text": "Alternative activation of the MEK/ERK pathway and NF-\u03baB by TPL2 contribute to ADI prostate cancer cell growth"
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20935675", 
                "endSection": "title", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 113, 
                "text": "Loss of tumor progression locus 2 (tpl2) enhances tumorigenesis and inflammation in two-stage skin carcinogenesis"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20935675", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 170, 
                "offsetInEndSection": 281, 
                "text": " Previously identified as an oncogene, its mutation or overexpression is reported in a variety of human cancers"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20935675", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1189, 
                "offsetInEndSection": 1390, 
                "text": "These studies indicate that Tpl2 may serve more as a tumor suppressor than as an oncogene in chemically induced skin carcinogenesis, with its absence contributing to both tumorigenesis and inflammation"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15575964", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1073, 
                "offsetInEndSection": 1176, 
                "text": "Studies in human tumor specimens have shown that Tpl2/Cot is overexpressed in early stage breast cancer"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15575964", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1182, 
                "offsetInEndSection": 1303, 
                "text": "in EBV-related Hodgkin lymphomas and nasopharyngeal carcinomas [10] and occasionally in gastric and colon adenocarcinomas"
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15575964", 
                "endSection": "title", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 62, 
                "text": "Expression of the Tpl2/Cot oncogene in human T-cell neoplasias"
            }, 
            {
                "beginSection": "sections.1", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15575964", 
                "endSection": "sections.1", 
                "offsetInBeginSection": 3190, 
                "offsetInEndSection": 3467, 
                "text": "ll the Tpl2/Cot overexpressing patients had LGL-PD, three with the phenotype of CD3+ T-LGL leukemia and one with the CD3- pattern of chronic NK-lymphocytosis. Three of these patients displayed neutropenia not attributable to BM infiltration, one in association with sarcoidosis"
            }
        ], 
        "triples": [
            {
                "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/TPL2", 
                "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/associatedGene", 
                "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3003"
            }
        ], 
        "type": "list"
    }, 
        {
        "body": "Which species may be used for the biotechnological production of itaconic acid?", 
        "concepts": [
            "http://www.biosemantics.org/jochem#4276340", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005656", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001426", 
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0047370", 
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0047613"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/23420787", 
            "http://www.ncbi.nlm.nih.gov/pubmed/23397482", 
            "http://www.ncbi.nlm.nih.gov/pubmed/23298766", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22956279", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22925689", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22752264", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22480369", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21324422", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20461508", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17697977", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17451943", 
            "http://www.ncbi.nlm.nih.gov/pubmed/12146646", 
            "http://www.ncbi.nlm.nih.gov/pubmed/1366363"
        ], 
        "exact_answer": [
            [
                "Aspergillus terreus"
            ], 
            [
                "Aspergillus niger"
            ], 
            [
                "Ustilago maydis"
            ]
        ], 
        "id": "515ffc2b298dcd4e51000035", 
        "ideal_answer": "In 1955, the production of itaconic acid was firstly described for Ustilago maydis.  Some Aspergillus species, like A. itaconicus and A. terreus, show the ability to synthesize this organic acid and A. terreus can secrete significant amounts to the media. Itaconic acid is mainly supplied by biotechnological processes with the fungus Aspergillus terreus. Cloning of the cadA gene into the citric acid producing fungus A. niger showed that it is possible to produce itaconic acid also in a different host organism.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/1366363", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 4, 
                "offsetInEndSection": 77, 
                "text": "continuous itaconic acid production from sucrose with Aspergillus terreus"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/12146646", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 104, 
                "text": "A potent itaconic acid producing strain, Aspergillus terreus SKR10, was isolated from horticulture waste"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/12146646", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 526, 
                "offsetInEndSection": 614, 
                "text": "Two high itaconic acid yielding mutants, N45 and UNCS1 were obtained by gradient plating"
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17451943", 
                "endSection": "title", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 87, 
                "text": "Itaconic acid production using sago starch hydrolysate by Aspergillus terreus TN484-M1."
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17697977", 
                "endSection": "title", 
                "offsetInBeginSection": 34, 
                "offsetInEndSection": 110, 
                "text": "production of itaconic acid and lovastatin by Aspergillus terreus ATCC 20542"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17697977", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 201, 
                "text": "Fermentation products of Aspergillus terreus ATCC 20542 (a parent strain for lovastatin production) were collected, and the coexistence of itaconic acid (IA) with lovastatin was confirmed in this study"
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20461508", 
                "endSection": "title", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 57, 
                "text": "Enhancing itaconic acid production by Aspergillus terreus"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20461508", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 83, 
                "text": "Aspergillus terreus is successfully used for industrial production of itaconic acid"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21324422", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 250, 
                "offsetInEndSection": 444, 
                "text": "From a number of different Aspergillus terreus controlled batch fermentations, those cultures with the largest difference in itaconic acid titer and productivity were selected for mRNA isolation"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22480369", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 942, 
                "offsetInEndSection": 1040, 
                "text": "itaconic acid is mainly supplied by biotechnological processes with the fungus Aspergillus terreus"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22480369", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 2024, 
                "offsetInEndSection": 2100, 
                "text": "In 1955, the production of itaconic acid was firstly described for U. maydis"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22752264", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 236, 
                "offsetInEndSection": 335, 
                "text": " a systematic process optimization was performed with an own isolated strain of Aspergillus terreus"
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22925689", 
                "endSection": "title", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 54, 
                "text": "Enhanced itaconic acid production in Aspergillus niger"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22925689", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 301, 
                "offsetInEndSection": 373, 
                "text": "Currently, itaconic acid is produced commercially by Aspergillus terreus"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22925689", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 696, 
                "offsetInEndSection": 888, 
                "text": "Based on its high citric acid producing capability and broad applicability in industry, Aspergillus niger (A. niger) was selected as a novel itaconic acid production host strain in recent work"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22925689", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1978, 
                "offsetInEndSection": 2111, 
                "text": "Therefore, over-expression of gpdA in A. niger CAD strains might increase itaconic acid producing level via enhanced glycolytic flux."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22956279", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 151, 
                "text": "Cells of Aspergillus terreus, free and immobilized in polyurethane foam, were employed in itaconic acid fermentation processes on glycerol-based media."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23298766", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 206, 
                "offsetInEndSection": 306, 
                "text": "current biotechnological production processes with the fungus Aspergillus terreus has to be improved"
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23397482", 
                "endSection": "title", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 115, 
                "text": "Reduced by-product formation and modified oxygen availability improve itaconic acid production in Aspergillus niger"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23397482", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 140, 
                "offsetInEndSection": 304, 
                "text": " Previously, it was shown that expression of the cis-aconitate decarboxylase gene (cadA) from Aspergillus terreus converted A. niger into an itaconic acid producer "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23420787", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 768, 
                "offsetInEndSection": 926, 
                "text": "Cloning of the cadA gene into the citric acid producing fungus A. niger showed that it is possible to produce itaconic acid also in a different host organism."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22480369", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1590, 
                "offsetInEndSection": 1705, 
                "text": "In this current study, itaconic acid fermentation was carried out with the mould fungus Ustilago maydis (U. maydis)"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23420787", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 247, 
                "offsetInEndSection": 416, 
                "text": "Some Aspergillus species, like A. itaconicus and A. terreus, show the ability to synthesize this organic acid and A. terreus can secrete significant amounts to the media"
            }
        ], 
        "type": "list"
    }, 
       {
        "body": "Which histone marks are deposited by Set7?", 
        "concepts": [
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0042393", 
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0016571", 
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0016570", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006657", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011495", 
            "http://www.uniprot.org/uniprot/SETD7_HALRO"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/21963854", 
            "http://www.ncbi.nlm.nih.gov/pubmed/15200950", 
            "http://www.ncbi.nlm.nih.gov/pubmed/12208845", 
            "http://www.ncbi.nlm.nih.gov/pubmed/12086618"
        ], 
        "exact_answer": [
            [
                "H4K20 monomethylation"
            ], 
            [
                "H3K4 monomethylation"
            ]
        ], 
        "id": "5160412d298dcd4e5100003c", 
        "ideal_answer": "Set7 is  H4K20 monomethyltransferase. Upregulation of PR-Set7 expression upon loss of HCF-1 leads to improper mitotic H4-K20 methylation. Set7 (or some variant) has also been reported to perform mono-methylation on lysine-4 of H3.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/12086618", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 190, 
                "offsetInEndSection": 226, 
                "text": "the loss of H4 lysine 20 methylation"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/12086618", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 286, 
                "offsetInEndSection": 351, 
                "text": "Transcriptionally competent regions lack H4 lysine 20 methylation"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/12086618", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 17, 
                "offsetInEndSection": 102, 
                "text": "a human histone H4 lysine 20 methyltransferase and cloned the encoding gene, PR/SET07"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/12208845", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 338, 
                "offsetInEndSection": 433, 
                "text": "Localization of PR-Set7 to mitotic chromosomes and subsequent increase in H4 Lys 20 methylation"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15200950", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 698, 
                "offsetInEndSection": 842, 
                "text": "the H4-K20 methyltransferase PR-Set7. Indeed, upregulation of PR-Set7 expression upon loss of HCF-1 leads to improper mitotic H4-K20 methylation"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21963854", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 3180, 
                "offsetInEndSection": 3263, 
                "text": "SET7 performs mono-methylation on lysine-4 of H3 to exert its coactivation function"
            }
        ], 
        "type": "list"
    }
]}
